Skip to content

Phytosome prepared from wild Pistacia Atlantica oleoresin on symptomatic and spirometric improvement of patients with asthma

Evaluation of the effect of oral phytosome prepared from wild Pistacia atlantica oleoresin on symptomatic and spirometric improvement of patients with moderate to severe asthma compared with standard treatment: a randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20100420003760N5
Enrollment
104
Registered
2022-11-08
Start date
2022-10-30
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Intervention group: receive the first dose(50) of phytosome formulation containing wild pistachio oleoresin in addition to conventional treatment. Intervention 2: Intervention group: r

Sponsors

Khoram-Abad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 15 years and older referring to the asthma and allergy specialist's office with a diagnosis of moderate or severe allergic asthma

Exclusion criteria

Exclusion criteria: Having other respiratory diseases except asthma Pregnant and lactating women or with a desire to become pregnant People with a history of drug allergy Taking anti-leukotriene drugs People who use supplements or other inhalation and non-inhalation drugs beyond what is allowed in this study. Having other special diseases such as kidney disease, tumor, etc.

Design outcomes

Primary

MeasureTime frame
The times of waking up with an asthma attack during the past week (zero to six according to the questionnaire); The severity of symptoms during the past week (zero to six according to the questionnaire); The amount of restriction in daily activities during the past week (zero to six according to the questionnaire); the severity of breath during the past week (zero to six according to the questionnaire); wheezing during the past week (zero to six according to the questionnaire).The daily puffs of short-acting inhaled bronchodilators used during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Rashidipour

Khoram-Abad University of Medical Sciences

m_rashidi80@yahoo.com+98 66 3320 4005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026